DECOY THERAPEUTICS INC
DCOYNASDAQ🏆 #5221 by market capEarnings Nov 13US Equity
$839.35▼ $65.89 (−7.85%)
Simulated priceTrack DCOY
Get earnings, price moves & breaking news on Telegram
24h▼ 7.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$4M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
48.6%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
18.8x
Expensive
Otter Score
64
Fair
No chart data available for DCOY.
Trading Snapshot
- Day Range
- $835.83 – $853.41
- 52-Week Range
- $2.18 – $55.92
- Volume
- $1.97B
- Avg Volume
- $2.02B
- Shares Outstanding
- 530,000
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $225,773
- Last Q Revenue
- $58,247
- P/E Ratio
- —
- P/S Ratio
- 18.8x
- EPS (TTM)
- $-934.89
- Dividend Yield
- —
- Dilution (1yr)
- +401.3%
Why Investors Own DCOY
- ✓High-growth profile — revenue up +37.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
DECOY THERAPEUTICS INC
DCOYFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▲ +120.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▲ +6.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
482K▲ +401.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$11M▲ +$8M YoY
StockOtter · stockotter.spaceAbout DECOY THERAPEUTICS INC
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100
Analyst Price Target
ⓘAverage Target
$807.86
▼ −3.8% Downside
High Target$996.19
Low Target$754.51
Based on 12 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
DECOY THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift DCOY price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
DECOY THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.